Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization

References

• Aaronson DS, Horvath CM. 2002. A road map for those who don't know JAK-STAT. Science. 296:1653–1655.
   PubMed Web of Science ®Google Scholar
• Adkins D, Ley J, Oppelt P, Wildes TM, Gay HA, Daly M, Rich J, Paniello RC, Jackson R, Pipkorn P, et al. 2017. Nab-paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncol. 72:26–31.
   PubMed Web of Science ®Google Scholar
• Ahn J, Truesdell P, Meens J, Kadish C, Yang X, Boag AH, Craig AWB. 2013. Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis. Mol Cancer Res. 11:952–963.
   PubMed Web of Science ®Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, et al. 2014. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950.
   PubMed Web of Science ®Google Scholar
• Bai J, Guo XG, Bai XP. 2012. Epidermal growth factor receptor-related DNA repair and radiation-resistance regulatory mechanisms: a mini-review. Asian Pac J Cancer Prev. 13:4879–4881.
   PubMedGoogle Scholar
• Baumann M, Krause M, Dikomey E, Dittmann K, Dörr W, Kasten-Pisula U, Rodemann HP. 2007. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 83:238–248.
   PubMed Web of Science ®Google Scholar
• Bergeron JJM, Di Guglielmo GM, Dahan S, Dominguez M, Posner BI. 2016. Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction. Annu Rev Biochem. 85:573–597.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh JW. 2013. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 119:1768–1775.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. 2012. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 7:1211–1217.
   PubMed Web of Science ®Google Scholar
• Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, et al. 2014. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. Am J Clin Oncol. 37:162–166.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. 2011. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 29:2312–2318.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. 2010. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11:21–28.
   PubMed Web of Science ®Google Scholar
• Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. 2016. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. 7:74362–74379.
   PubMedGoogle Scholar
• Bouras A, Kaluzova M, Hadjipanayis CG. 2015. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles. J Neurooncol. 124:13–22.
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. 2013. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 108:370–377.
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, et al. 2014. AXL mediates resistance to cetuximab therapy. Cancer Res. 74:5152–5164.
   PubMed Web of Science ®Google Scholar
• Bussink J, van der Kogel AJ, Kaanders JH. 2008. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 9:288–296.
   PubMed Web of Science ®Google Scholar
• Cao X, Zhu H, Ali-Osman F, Lo HW. 2011. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Mol Cancer. 10:26.
   PubMed Web of Science ®Google Scholar
• Carpenter G. 2003. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol. 15:143–148.
   PubMed Web of Science ®Google Scholar
• Chang CC, Chi KH, Kao SJ, Hsu PS, Tsang YW, Chang HJ, Yeh YW, Hsieh YS, Jiang JS. 2011. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 73:189–194.
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM. 2005. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65:3328–3335.
   PubMed Web of Science ®Google Scholar
• Chen G-Z, Dai W-S, Zhu H-C, Song H-M, Yang X, Wang Y-D, Min H, Lu Q, Liu S, Sun X-C, et al. 2017. Foretinib enhances the radiosensitivity in esophageal squamous cell carcinoma by inhibiting phosphorylation of c-Met. J Cancer. 8:983–992.
   PubMed Web of Science ®Google Scholar
• Chitnis MM, Lodhia K, Aleksic T, Gao S, Protheroe AS, Macaulay VM. 2014. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene. 33:5262–5273.
   PubMed Web of Science ®Google Scholar
• Chou R-H, Wang Y-N, Hsieh Y-H, Li L-Y, Xia W, Chang W-C, Chang L-C, Cheng C-C, Lai C-C, Hsu JL, et al. 2014. EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. Dev Cell. 30:224–237.
   PubMed Web of Science ®Google Scholar
• Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature. 464:783–787.
   PubMed Web of Science ®Google Scholar
• Cohen RB. 2014. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev. 40:567–577.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Campo JM, Mailliez A, Haddad RI. 2017. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 28:2526–2532.
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. 2007. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene. 26:2423–2434.
   PubMed Web of Science ®Google Scholar
• Cuneo KC, Nyati MK, Ray D, Lawrence TS. 2015. EGFR targeted therapies and radiation: optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther. 154:67–77.
   PubMed Web of Science ®Google Scholar
• De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C. 2011. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 103:645–661.
   PubMedGoogle Scholar
• De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S. 2015. Reversal of Warburg effect and reactivation of oxidative Phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res. 21:5110–5120.
   PubMed Web of Science ®Google Scholar
• Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I, Hüttemann M, Douglas R, Haddad G, Parsons SJ. 2009. Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J Biol Chem. 284:36592–36604.
   PubMed Web of Science ®Google Scholar
• Desai S, Kumar A, Laskar S, Pandey BN. 2013. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine. 61:54–62.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP. 2005. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 280:31182–31189.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Kehlbach R, Rodemann HP. 2008. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 7:69.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Paasch A, Huber S, Fehrenbacher B, Schaller M, Rodemann HP. 2015. Nuclear EGFR renders cells radio-resistant by binding mRNA species and triggering a metabolic switch to increase lactate production. Radiother Oncol. 116:431–437.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Rodemann HP. 2005. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol. 76:157–161.
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Rodemann HP. 2010. Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol. 186:1–6.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Pirker R, O’Byrne KJ, Kerr KM, Störkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA. 2014. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non–small-cell lung cancer. J Thorac Oncol. 9:717–724.
   PubMed Web of Science ®Google Scholar
• Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, et al. 2012. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci USA. 109:1643–1648.
   PubMed Web of Science ®Google Scholar
• Du Y, Grandis JR. 2015. Receptor-type protein tyrosine phosphatases in cancer. Chin J Cancer. 34:61–69.
   PubMed Web of Science ®Google Scholar
• Du Y, Peyser ND, Grandis JR. 2014. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther. 142:88–98.
   PubMed Web of Science ®Google Scholar
• Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, Reynolds AB, Chen J. 2017. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci. Signal. 10:4667.
   Web of Science ®Google Scholar
• Eke I, Ingargiola M, Förster C, Kunz-Schughart LA, Baumann M, Runge R, Freudenberg R, Kotzerke J, Heldt J-M, Pietzsch H-J, et al. 2014. Cytotoxic properties of radionuclide-conjugated cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro. Int J Radiat Biol. 90:678–686.
   PubMed Web of Science ®Google Scholar
• Eke I, Sandfort V, Storch K, Baumann M, Röper B, Cordes N. 2007. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. Int J Radiat Biol. 83:793–802.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Stigbrand T. 2010. Radiation-induced cell death mechanisms. Tumour Biol. 31:363–372.
   PubMed Web of Science ®Google Scholar
• Fehrmann A, Dörr W. 2005. Effect of EGFR-inhibition on the radiation response of oral mucosa: experimental studies in mouse tongue epithelium. Int J Radiat Biol. 81:437–443.
   PubMed Web of Science ®Google Scholar
• Ferte C, Loriot Y, Clemenson C, Commo F, Gombos A, Bibault J-E, Fumagalli I, Hamama S, Auger N, Lahon B, et al. 2013. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy. Mol Cancer Ther. 12:1213–1222.
   PubMed Web of Science ®Google Scholar
• Gao B, Roux PP. 2015. Translational control by oncogenic signaling pathways. Biochim Biophys Acta. 1849:753–765.
   PubMedGoogle Scholar
• Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, O’Byrne KJ. 2014. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer. 15:58–66.
   PubMed Web of Science ®Google Scholar
• Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ. 2013. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther. 12:2541–2558.
   PubMed Web of Science ®Google Scholar
• Gouazé-Andersson V, Delmas C, Taurand M, Martinez-Gala J, Evrard S, Mazoyer S, Toulas C, Cohen-Jonathan-Moyal E. 2016. FGFR1 induces glioblastoma radioresistance through the PLCγ/Hif1α pathway. Cancer Res. 76:3036–3044.
   PubMed Web of Science ®Google Scholar
• Guryanova OA, Bao S. 2011. How scatter factor receptor c-MET contributes to tumor radioresistance: ready, set, scatter! J Natl Cancer Inst. 103:617–619.
   PubMedGoogle Scholar
• Hainsworth JD, Spigel DR, Greco FA, Shipley DL, Peyton J, Rubin M, Stipanov M, Meluch A. 2011. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 17:267–272.
   PubMed Web of Science ®Google Scholar
• Han W, Lo HW. 2012. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318:124–134.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674.
   PubMed Web of Science ®Google Scholar
• Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, et al. 2014. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 32:2486–2495.
   PubMed Web of Science ®Google Scholar
• Harari PM, Huang S. 2006. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol. 16:38–44.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Solca F, Gauler TC. 2014. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Future Oncol. 10:21–40.
   PubMed Web of Science ®Google Scholar
• Hay N. 2016. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 16:635–649.
   PubMed Web of Science ®Google Scholar
• Heavey S, O'Byrne KJ, Gately K. 2014. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev. 40:445–456.
   PubMed Web of Science ®Google Scholar
• Herchenhorn D, Dias FL, Viegas CMP, Federico MH, Araújo CMM, Small I, Bezerra M, Fontão K, Knust RE, Ferreira CG, et al. 2010. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Intl J Radiat Oncol Biol Phys. 78:696–702.
   PubMed Web of Science ®Google Scholar
• Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, LeRoith D. 2001. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem. 276:18185–18192.
   PubMedGoogle Scholar
• Hitosugi T, Fan J, Chung T-W, Lythgoe K, Wang X, Xie J, Ge Q, Gu T-L, Polakiewicz RD, Roesel JL, et al. 2011. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 44:864–877.
   PubMed Web of Science ®Google Scholar
• Isebaert SF, Swinnen JV, McBride WH, Haustermans KM. 2011. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int J Radiat Oncol Biol Phys. 81:239–247.
   PubMed Web of Science ®Google Scholar
• Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K. 2009. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res. 15:5117–5125.
   PubMed Web of Science ®Google Scholar
• Jeggo PA, Geuting V, Löbrich M. 2011. The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol. 101:7–12.
   PubMed Web of Science ®Google Scholar
• Kao H-W, Lin Y-Y, Chen C-C, Chi K-H, Tien D-C, Hsia C-C, Lin M-H, Wang H-E. 2013. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorg Med Chem Lett. 23:3180–3185.
   PubMed Web of Science ®Google Scholar
• Keller J, Shroyer KR, Batajoo SK, Zhao H, Dong LM, Hayman MJ, Chan EL. 2010. Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer. Cancer Invest. 28:1054–1062.
   PubMed Web of Science ®Google Scholar
• Khoo A, Sahoo N, Krishnan S, Diagaradjane P. 2016. Enhancing the relative biological effectiveness of proton therapy using EGFR-targeted gold nanorods. Intl J Radiat Oncol Biol Phys. 96:S236.
   Web of Science ®Google Scholar
• Kim JH, Jenrow KA, Brown SL. 2014. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat Oncol J. 32:103–115.
   PubMedGoogle Scholar
• Kiyozuka M, Akimoto T, Fukutome M, Motegi A, Mitsuhashi N. 2013. Radiation-induced dimer formation of EGFR: implications for the radiosensitizing effect of cetuximab. Anticancer Res. 33:4337–4346.
   PubMed Web of Science ®Google Scholar
• Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. 2015. Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 92:317–324.
   PubMed Web of Science ®Google Scholar
• Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. 2014. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 112:30–36.
   PubMed Web of Science ®Google Scholar
• Krall JA, Beyer EM, MacBeath G. 2011. High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One. 6:e15945.
   PubMed Web of Science ®Google Scholar
• Kumar A, Desai S, Pandey BN. 2013. Endothelial Dll4-notch signaling in tumor microenvironment: is there any hidden therapeutic opportunity. Transl Lung Cancer Res. 2:439–441.
   PubMedGoogle Scholar
• Lanning NJ, Castle JP, Singh SJ, Leon AN, Tovar EA, Sanghera A, MacKeigan JP, Filipp FV, Graveel CR. 2017. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. Cancer Metab. 5:6.
   PubMed Web of Science ®Google Scholar
• Lee CK, Wu Y-L, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, et al. 2015. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR -mutant lung cancer: a meta-analysis. JCO. 33:1958–1965.
   PubMed Web of Science ®Google Scholar
• Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK. 2005. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 99:415–421.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim SY, Kil IS, Park JW. 2007. Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 282:13385–13394.
   PubMed Web of Science ®Google Scholar
• Li HF, Kim JS, Waldman T. 2009. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 4:43.
   PubMed Web of Science ®Google Scholar
• Li P, Veldwijk MR, Zhang Q, Li Z, Xu W, Fu S. 2013. Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells. BMC Cancer. 13:297.
   PubMed Web of Science ®Google Scholar
• Li X, Lian Z, Wang S, Xing L, Yu J. 2018. Interactions between EGFR and PD-1/PD-L1 pathway: implications for treatment of NSCLC. Cancer Lett. 418:1–9.
   PubMed Web of Science ®Google Scholar
• Liccardi G, Hartley JA, Hochhauser D. 2011. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 71:1103–1114.
   PubMed Web of Science ®Google Scholar
• Liccardi G, Hartley JA, Hochhauser D. 2014. Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage. Clin Cancer Res. 20:3496–3506.
   PubMed Web of Science ®Google Scholar
• Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, Kim CH. 2012. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol. 48:1114–1119.
   PubMed Web of Science ®Google Scholar
• Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. 2006. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1. J Cell Biochem. 98:1570–1583.
   PubMed Web of Science ®Google Scholar
• Lo YH, Ho PC, Wang SC. 2012. Epidermal growth factor receptor protects proliferating cell nuclear antigen from cullin 4A protein-mediated proteolysis. J Biol Chem. 287:27148–27157.
   PubMed Web of Science ®Google Scholar
• Macha M, Rachagani S, Qazi AK, Jahan R, Gupta S, Patel A, Seshacharyulu P, Lin C, Li S, Wang S, et al. 2017. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget. 8:20961–20973.
   PubMedGoogle Scholar
• Mahajan K, Mahajan NP. 2015. Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res. 43:10588–10601.
   PubMed Web of Science ®Google Scholar
• Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H, Tsuchihara K. 2014. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem. 289:20813–20823.
   PubMed Web of Science ®Google Scholar
• Martinez E, Martinez M, Rico M, Hernandez B, Casas F, Vinolas N, Perez-Casas A, Domine M, Minguez J. 2016. Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a phase II trial. Onco Targets Ther. 9:1057–1066.
   PubMed Web of Science ®Google Scholar
• Mehta VK. 2012. Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. Front Oncol. 2:31.
   PubMedGoogle Scholar
• Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, Vigo V, Bacigalupo A, Numico G, Crosetto N, et al. 2011. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol. 22:712–717.
   PubMed Web of Science ®Google Scholar
• Milas L, Mason KA, Ang KK. 2003. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int J Radiat Biol. 79:539–545.
   PubMed Web of Science ®Google Scholar
• Mir Y, Elrington SA, Hasan T. 2013. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomedicine. 9:1114–1122.
   PubMed Web of Science ®Google Scholar
• Miyata T, Toho T, Nonoguchi N, Furuse M, Kuwabara H, Yoritsune E, Kawabata S, Kuroiwa T, Miyatake S-I. 2014. The roles of platelet-derived growth factors and their receptors in brain radiation necrosis. Radiat Oncol. 9:51.
   PubMed Web of Science ®Google Scholar
• Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li J-L, Bridges E, et al. 2014. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5:5934–5949.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Jeppesen M, Pilgaard L, Agger R, Duroux M, Zachar V, Moos T. 2013. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J Drug Deliv. 2013:209205.
   PubMedGoogle Scholar
• Mu X, Ma J, Zhang Z, Zhou H, Xu S, Qin Y, Huang J, Yang K, Wu G. 2015. Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation. Int J Radiat Biol. 91:771–776.
   PubMed Web of Science ®Google Scholar
• Muthusami S, Prabakaran DS, Yu JR, Park WY. 2015. FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in cervical cancer cells. J Cancer Res Clin Oncol. 141:203–210.
   PubMed Web of Science ®Google Scholar
• Nakada M, Kita D, Teng L, Pyko IV, Watanabe T, Hayashi Y, Hamada JI. 2013. Receptor tyrosine kinases: principles and functions in glioma invasion. Adv Exp Med Biol. 986:143–170.
   PubMed Web of Science ®Google Scholar
• Nyati M, Morgan M, Feng F, Lawrence T. 2006. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 6:876–885.
   PubMed Web of Science ®Google Scholar
• Ortega J, Li JY, Lee S, Tong D, Gu L, Li GM. 2015. Phosphorylation of PCNA by EGFR inhibits mismatch repair and promotes misincorporation during DNA synthesis. Proc Natl Acad Sci USA. 112:5667–5672.
   PubMed Web of Science ®Google Scholar
• Pandey BN, Mishra KP. 1999. Radiation induced oxidative damage modification by cholesterol in liposomal membrane. Radiat. Phys Chem. 54:481–489.
   Google Scholar
• Pavlova NN, Thompson CB. 2016. The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47.
   PubMed Web of Science ®Google Scholar
• Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S. 2015. Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck. 37:763–770.
   PubMed Web of Science ®Google Scholar
• Petrilli R, Eloy J, Lopez R, Lee R. 2017. Cetuximab immunoliposomes enhances delivery of 5-FU to skin squamous carcinoma cells. ACAMC. 17:301–308.
   Google Scholar
• Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy SR, Lanuti M, Fintelmann FJ, Lennes I, Farago A, et al. 2017. Heterogeneity and variation in resistance mechanisms among 223 epidermal growth factor receptor–mutant non–small cell lung cancer patients with >1 post-resistance biopsy. Intl J Radiat Oncol Biol Phys. 98:220.
   Web of Science ®Google Scholar
• Poliaková M, Aebersold DM, Zimmer Y, Medová M. 2018. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Mol Cancer. 17:27.
   PubMed Web of Science ®Google Scholar
• Popovtzer A, Mizrachi A, Motiei M, Bragilovski D, Lubimov L, Levi M, Hilly O, Ben-Aharon I, Popovtzer R. 2016. Actively targeted gold nanoparticles as novel radiosensitizer agents: an in vivo head and neck cancer model. Nanoscale. 8:2678–2685.
   PubMed Web of Science ®Google Scholar
• Qian L-W, Mizumoto K, Inadome N, Nagai E, Sato N, Matsumoto K, Nakamura T, Tanaka M. 2003. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer. 104:542–549.
   PubMed Web of Science ®Google Scholar
• Qian Y, Qiu M, Wu Q, Tian Y, Zhang Y, Gu N, Li S, Xu L, Yin R. 2014. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Sci Rep. 4:7490.
   PubMed Web of Science ®Google Scholar
• Raju U, Molkentine DP, Valdecanas DR, Deorukhkar A, Mason KA, Buchholz TA, Meyn RE, Ang K-K, Skinner H. 2015. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit. Cancer Med. 4:65–74.
   PubMed Web of Science ®Google Scholar
• Raju U, Riesterer O, Wang Z-Q, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK. 2012. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol. 105:241–249.
   PubMed Web of Science ®Google Scholar
• Regad T. 2015. Targeting RTK signaling pathways in cancer. Cancers (Basel). 7:1758–1784.
   PubMed Web of Science ®Google Scholar
• Rettew AN, Getty PJ, Greenfield EM. 2015. Receptor tyrosine kinases in osteosarcoma: not just the usual suspects. Adv Exp Med Biol. 804:66–74.
   Web of Science ®Google Scholar
• Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch C-J, Petersen C, Dikomey E, Kriegs M. 2013. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol. 107:242–246.
   PubMed Web of Science ®Google Scholar
• Rodemann HP, Dittmann K, Toulany M. 2007. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol. 83:781–791.
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Adelstein DJ, Rybicki LA, Saxton JP, Lorenz RR, Wood BG, Scharpf J, Ives DI. 2012. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. Head Neck. 34:1517–1523.
   PubMed Web of Science ®Google Scholar
• Santivasi WL, Xia F. 2014. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 21:251–259.
   PubMed Web of Science ®Google Scholar
• Savvides P, Agarwala SS, Greskovich J, Argiris A, Bokar J, Cooney M, Hoppel C, Stepnick DW, Lavertu P, Remick S. 2006. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 24:5545.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Fayette J, Cupissol D, Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, et al. 2014. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 25:1813–1820.
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You W-K, Chapman HA, Christensen JG, et al. 2012. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2:270–287.
   PubMed Web of Science ®Google Scholar
• She Q-B, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 8:287–297.
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. 2017. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 17:20–37.
   PubMed Web of Science ®Google Scholar
• Shibuya M. 2006. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 9:225–230.
   PubMedGoogle Scholar
• Shinomiya N. 2001. New concepts in radiation-induced apoptosis: “premitotic apoptosis” and “postmitotic apoptosis”. J Cellular Mol Med. 5:240–253.
   PubMed Web of Science ®Google Scholar
• Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, et al. 2017. Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res. 23:2713–2722.
   PubMed Web of Science ®Google Scholar
• Song L, Falzone N, Vallis KA. 2016. EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer. Int J Radiat Biol. 92:716–723.
   PubMed Web of Science ®Google Scholar
• Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC. 2018. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions. Lung Cancer. 115:12–20.
   PubMed Web of Science ®Google Scholar
• Spina A, De Pasquale V, Cerulo G, Cocchiaro P, Della Morte R, Avallone L, Pavone L. 2015. HGF/c-MET axis in tumor microenvironment and metastasis formation. Biomedicines. 3:71–88.
   PubMed Web of Science ®Google Scholar
• Sridharan V, Sharma SK, Moros EG, Corry PM, Tripathi P, Lieblong BJ, Guha C, Hauer-Jensen M, Boerma M. 2013. Effects of radiation on the epidermal growth factor receptor pathway in the heart. Int J Radiat Biol. 89:539–547.
   PubMed Web of Science ®Google Scholar
• Stahler C, Roth J, Cordes N, Taucher-Scholz G, Mueller-Klieser W. 2013. Impact of carbon ion irradiation on epidermal growth factor receptor signaling and glioma cell migration in comparison to conventional photon irradiation. Int J Radiat Biol. 89:454–461.
   PubMed Web of Science ®Google Scholar
• Stokes WA, Sumner WA, Breggren KL, Rathbun JT, Raben D, McDermott JD, Gan G, Karam SD. 2017. A comparison of concurrent cisplatin versus cetuximab with radiotherapy in locally-advanced head and neck cancer: a bi-institutional analysis. Rep Pract Oncol Radiother. 22:389–395.
   PubMedGoogle Scholar
• Sun C, Bernards R. 2014. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci. 39:465–474.
   PubMed Web of Science ®Google Scholar
• Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, et al. 2017. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 3:1520–1528.
   PubMed Web of Science ®Google Scholar
• Szentkúti G, Dános K, Brauswetter D, Kiszner G, Krenács T, Csákó L, Répássy G, Tamás L. 2015. Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas. Pathol Oncol Res. 21:643–650.
   PubMed Web of Science ®Google Scholar
• Tan X, Lambert PF, Rapraeger AC, Anderson RA. 2016. Stress-induced EGFR trafficking: mechanisms, functions, and therapeutic implications. Trends Cell Biol. 26:352–366.
   PubMed Web of Science ®Google Scholar
• Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, Peruzzi F, Khalili K, Skorski T, Reiss K. 2003. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cellular Biol. 23:7510–7524.
   PubMed Web of Science ®Google Scholar
• Tumati V, Kumar S, Yu L, Chen B, Choy H, Saha D. 2013. Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncol Rep. 29:1094–1100.
   PubMed Web of Science ®Google Scholar
• Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, Rochester M, Protheroe AS, Brewster SF, Macaulay VM. 2012. Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol. 103:402–409.
   PubMed Web of Science ®Google Scholar
• Van Waes C, Allen CT, Citrin D, Gius D, Colevas AD, Harold NA, Rudy S, Nottingham L, Muir C, Chen Z, et al. 2010. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 77:447–454.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, et al. 2008. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127.
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, et al. 2014. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 25:2036–2041.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yuan JL, Zhang YT, Ma JJ, Xu P, Shi CH, Zhang W, Li YM, Fu Q, Zhu GF, et al. 2013. Inhibition of both EGFR and IGF1R sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repair. PLoS One. 8:e68784.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ellis P. 2017. EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors. Ann Transl Med. 5:424.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu XX, Wu XH, Li B, Shen T-Z, Kong Q-T, Li J, Li Z-B, Jiang W-R, Wang Y, et al. 2014. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non–small cell lung cancer. Am J Clin Oncol. 37:148–153.
   PubMed Web of Science ®Google Scholar
• Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, et al. 2017. KRAS-variant is a biomarker of cetuximab response potentially through altered immunity in head and neck cancer: re-analysis of NRG oncology/RTOG 0522. JAMA Oncol. 3:483–491.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. 2011. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 17:1359–1370.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. 2009. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 4:69.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, et al. 2013. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 31:895–902.
   PubMed Web of Science ®Google Scholar
• Wu TT, Zhou SH. 2015. Nanoparticle-based targeted therapeutics in head-and-neck cancer. Int J Med Sci. 12:187–200.
   PubMed Web of Science ®Google Scholar
• Yamamoto VN, Thylur DS, Bauschard M, Schmale I, Sinha UK. 2016. Overcoming radioresistance in head and neck squamous cell carcinoma. Oral Oncol. 63:44–51.
   PubMed Web of Science ®Google Scholar
• Yao M, Woods C, Lavertu P, Fu P, Gibson M, Rezaee R, Zender C, Wasman J, Sharma N, Machtay M, et al. 2016. Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. Head Neck. 38:E1770–E1776.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Shilo BZ. 2007. SnapShot: EGFR signaling pathway. Cell. 131:1018e2.
   PubMed Web of Science ®Google Scholar
• Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM, Chen J. 2016. The ephrin-A1/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer. Cancer Res. 76:1825–1836.
   PubMed Web of Science ®Google Scholar
• Yu H, Li X, Sun S, Gao X, Zhou D. 2012. C-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Biochem Biophys Res Commun. 427:659–665.
   PubMed Web of Science ®Google Scholar
• Yu Y-L, Chou R-H, Liang J-H, Chang W-J, Su K-J, Tseng Y-J, Huang W-C, Wang S-C, Hung M-C. 2013. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides. PLoS One. 8:e61362.
   PubMed Web of Science ®Google Scholar
• Zalba S, Contreras AM, Haeri A, Ten Hagen TLM, Navarro I, Koning G, Garrido MJ. 2015. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release. 210:26–38.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zheng X, Huang H, Wu K, Wang B, Chen X, Ma S. 2015. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget. 6:5832–5845.
   PubMedGoogle Scholar
• Zhang XY, Zhang PY. 2016. Receptor tyrosine kinases in carcinogenesis. Oncol Lett. 12:3679–3682.
   PubMed Web of Science ®Google Scholar